Highlights From the 2021 SABCS Symposium
  • CME

December 7-10, 2021; San Antonio, Texas
In this expert analysis, Joyce O’Shaughnessy, MD, and Sara Tolaney, MD, MPH, discuss clinically relevant new data on breast cancer presented at the 2021 SABCS Symposium.
Joyce O'Shaughnessy, MD
Sara Tolaney, MD, MPH
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: February 25, 2022 Expiration: February 24, 2023

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with early-stage or metastatic breast cancer
  • Identify subpopulations of patients with breast cancer most likely to benefit from a specific treatment plan based on prognostic or predictive markers
  • Discuss new data on novel agents and therapeutic approaches for patients with breast cancer

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Novartis Pharmaceuticals Corporation
Sanofi Genzyme
Seagen Inc.

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Director,
Breast Cancer Research Program
Baylor University Medical Center
Texas Oncology
US Oncology Network
Dallas, Texas

Joyce O’Shaughnessy, MD, has disclosed that she has received consulting fees from AbbVie, Agendia, Amgen, Aptitude, AstraZeneca, Bristol-Myers Squibb, Celgene, Eisai, G1 Therapeutics, Genentech, Immunomedics, Ipsen, Jounce, Lilly, Merck, Myriad, Novartis, Ondonate, Pfizer, Prime, Puma, Roche, Seattle Genetics, and Syndax.
Sara Tolaney, MD, MPH

Associate Professor of Medicine
Division of Breast Oncology
Harvard Medical School
Chief, Division of Breast Oncology
Breast Oncology Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Sara Tolaney, MD, MPH, has disclosed that she has received funds for research support (paid to her institution) from AstraZeneca, Bristol-Myers Squibb, Cyclacel, Eisai, Exelixis, Genentech, Immunomedics/Gilead, Lilly, Merck, Nanostring, Nektar, Novartis, Odonate, Pfizer, Sanofi, and Seattle Genetics and has received consulting fees from 4D Pharma, AstraZeneca, Athenex, BeyondSpring Pharmaceuticals, Bristol-Myers Squibb, Chugai, CytomX, Daiichi Sankyo, Eisai, Ellipses Pharma, Genentech, Immunomedics/Gilead, Infinity Therapeutics, Lilly, Mersana, Novartis, OncoPep, OncoSec, OncXerna, Pfizer, Puma, Samsung Bioepsis, Sanofi, Seattle Genetics, Zymeworks, and Zentalis.

Staff

Marie N. Becker, PhD

Scientific Director

Marie N. Becker, PhD, has no relevant conflicts of interest to report.
Elizabeth O’Connell, PhD
Elizabeth O’Connell, PhD, has no relevant conflicts of interest to report.
Krista Marcello

Senior Director, Educational Strategy
Hematology and Oncology

Krista Marcello has no relevant conflicts of interest to report.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Vice President, Scientific Services

Timothy Quill, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare professionals who care for patients with breast cancer.

Goal

The goal of this activity is to improve learners’ understanding of how to optimally apply recent practice-changing findings in the treatment of patients with breast cancer.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from February 25, 2022, through February 24, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Enter details about your patient with HER2+ MBC into this online tool from Clinical Care Options (CCO) to see treatment recommendations from 5 experts

Aditya Bardia, MD, MPH Sara Hurvitz, MD, FACP Komal Jhaveri, MD Heather McArthur, MD, MPH Sara Tolaney, MD, MPH Released: November 23, 2022

Expert commentary with Dr Charles Geyer on the essential need for BRCA testing in early breast cancer to guide adjuvant olaparib decisions, from Clinical Care Options (CCO) and ProCE

Charles E. Geyer, Jr., MD Released: November 17, 2022

A patient describes her journey with early breast cancer and the critical role of good communication between patients and their healthcare providers in this short video by Clinical Care Options (CCO)

person default Zoe Lanham Released: November 16, 2022

Downloadable slides on multidisciplinary approaches to managing high-risk, HR-positive/HER2-negative early breast cancer, from Clinical Care Options, (CCO)

Erika P. Hamilton, MD
Program Director
Joyce O'Shaughnessy, MD
Program Director
Released: November 16, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings